Moreover, of the 83 inhibitors, 20 are already in use for the treatment of LC in patients with ALK, BRAF, EGFR, ERBB2, MEK, MET, NTRK2 and RET alterations.11, 40. The gene discussed is ERBB2; the disease is laryngotracheoesophageal cleft.